Authors: Haymet A, Bassi GL, Fraser JF PMID: 33170330 PMCID: PMC7652914 DOI: 10.1007/s00134-020-06314-w Abstract In 2020, a new pandemic caused by SARS-CoV-2 was declared, and since the first cases of coronavirus disease 2019 (COVID-19), clinicians had to apply different modes of respiratory support, previously used on patients with severe respiratory failure from other etiologies. In [...]

More than 1.6 million Americans have been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and more than 10 times that number carry antibodies to it.

Authors: Woodruff MC, Ramoneli RP, Lee FE, Sanz I doi: https://doi.org/10.1101/2020.10.21.20216192 Abstract Severe SARS-CoV-2 infection is linked to the presence of autoantibodies against multiple targets, including phospholipids and type-I interferons. We recently identified activation of an autoimmune-prone B cell response pathway as correlate of severe COVID-19, raising the possibility of de novo autoreactive antibody production [...]

Authors: Magro CM, Mulvey JJ, Laurence J, seshan S, Crowson AN, Harp J PMID: 33058948 PMCID: PMC7550120 DOI: 10.1016/j.humpath.2020.10.002 Abstract The purpose of this study was to examine the deltoid skin biopsy in twenty-three patients with coronavirus disease 2019 (COVID-19), most severely ill, for vascular complement deposition and correlate this with severe acute respiratory syndrome [...]

Authors: Lehrer S, Rheinstein PH PMID: 32871846 PMCID: PMC7652439 DOI: 10.21873/invivo.12134 Abstract Background/aim: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). One drug that has attracted interest is the antiparasitic compound ivermectin, a macrocyclic lactone derived from the bacterium Streptomyces avermitilis. We carried out a docking [...]

Objective: To determine if hydroxychloroquine (HCQ) reduces the incidence of new illness, hospitalization or death among outpatients at risk for or infected with SARS-CoV-2 (COVID-19).

Authors: Kory P, Kanne JP PMID: 32963028 PMCID: PMC7509945 DOI: 10.1136/bmjresp-2020-000724 Abstract Reviews of COVID-19 CT imaging along with postmortem lung biopsies and autopsies indicate that the majority of patients with COVID-19 pulmonary involvement have secondary organising pneumonia (OP) or its histological variant, acute fibrinous and organising pneumonia, both well-known complications of viral infections. Further, [...]

Authors: Zaid Y, Puhm F, Allaeys I, Naya A, Oudghiri M PMID: 32938299 PMCID: PMC7641188 DOI: 10.1161/CIRCRESAHA.120.317703 Abstract Rationale: In addition to the overwhelming lung inflammation that prevails in COVID-19, hypercoagulation and thrombosis contribute to the lethality of subjects infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Platelets are chiefly implicated in thrombosis. Moreover, [...]

Conclusions: The results of this case series suggest that high-dose oral famotidine is well tolerated and associated with improved patient-reported outcomes in non-hospitalised patients with COVID-19.

Authors: Zhang S, Liu Y, Wang X, Yang L, Li H, Wang Y PMID: 32887634 PMCID: PMC7471641 DOI: 10.1186/s13045-020-00954-7 Abstract Background: Critically ill patients diagnosed with COVID-19 may develop a pro-thrombotic state that places them at a dramatically increased lethal risk. Although platelet activation is critical for thrombosis and is responsible for the thrombotic events [...]